Hopp til hovedinnhold

Malignt nevroleptikasyndrom

Malignt nevroleptikasyndrom er en komplikasjon til behandling med antipsykotika. Typiske tegn er endret mental status, muskelstivhet, ufrivillige bevegelser og feber.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/psykisk-helse/diverse/malignt-nevroleptikasyndrom/ 

Hva er malignt nevroleptikasyndrom?

Symptomer og tegn

Diagnosen

Behandling

Prognosen

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Malignt nevroleptikasyndrom. Referanselisten for dette dokumentet vises nedenfor.

  1. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. Published 2018 Jan 4. PMID: 29325237 PubMed 
  2. Wijdicks EFM. Neuroleptic malignant syndrome. UpToDate, last updated May 31, 2019. UpToDate 
  3. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012;24:155-162. PubMed 
  4. Benzer TI. Neuroleptic malignant syndrome. Medscape, last updated Feb 12, 2015. emedicine.medscape.com 
  5. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008;42;1290-1297.
  6. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69:1157-1165. PubMed 
  7. Dietrichs ES, Dietrichs E. Time to replace the term neuroleptic malignant syndrome with antidopaminergic syndrome?. Lancet Psychiatry 2022. doi:10.1016/S2215-0366(22)00108-0 DOI 
  8. Rosebush PI, Anglin RE, Richards C, et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol 2008;28:459-461. PubMed 
  9. Viejo LF, Morales V, Puñal P, Pérez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome: A case-control study. Acta Psychiatr Scand 2003; 107: 45-49. PubMed 
  10. Mitchell J, Jenkins-Welch M. Neuroleptic malignant syndrome. BMJ Best Practice, last updated 08 Sept, 2021.
  11. Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no 
  12. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005; 2: 125-7. pmid:15905757 PubMed 
  13. Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand 2021; 144: 329-341. pmid:34358327 PubMed 
  14. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry 2012; 57: 512-8. pmid:22854034 PubMed 
  15. Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry 2012; 73: 427-30. pmid:22154901 PubMed